Hidehito Horinouchi

Hidehito Horinouchi: Afatinib in patients with solid tumors with neuregulin1 (NRG1) fusions

Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, posted on X:

“Afatinib in patients with solid tumors with neuregulin 1 fusions: a case series from the TAPUR Study.

Efficacy of afatinib in lung, colorectal, and pancreatic cancers harboring NRG1 fusions – Dr. Jordi Rodon.”

“Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.”

Authors: Jordi Rodon et al.

Hidehito Horinouchi: Afatinib in patients with solid tumors with neuregulin1 (NRG1) fusions

cancer colorectal cancer Hidehito Horinouchi Jordi Rodon Lung cancer OncoDaily Oncology Pancreatic Cancer TAPUR study